Frankel A E, Kreitman R J, Sausville E A
Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Clin Cancer Res. 2000 Feb;6(2):326-34.
Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.
靶向毒素由与多肽毒素偶联的肿瘤选择性配体组成，是一类新型癌症治疗药物，通过使胞质蛋白合成失活并诱导细胞凋亡来杀死恶性细胞。其中一些分子已在良好生产规范条件下制备，并已全身给予患有各种肿瘤的患者。本文讨论了迄今为止取得的有前景的结果以及剩余的药理学障碍。
